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Abstract: Previous studies have shown that COPD adversely affects distant organs and body 
systems, including the brain. This pilot study aims to model the relationships between respira-
tory insufﬁ  ciency and domains related to brain function, including low mood, subtly impaired 
cognition, systemic inﬂ  ammation, and brain structural and neurochemical abnormalities. Nine 
healthy controls were compared with 18 age- and education-matched medically stable COPD 
patients, half of whom were oxygen-dependent. Measures included depression, anxiety, cogni-
tion, health status, spirometry, oximetry at rest and during 6-minute walk, and resting plasma 
cytokines and soluble receptors, brain MRI, and MR spectroscopy in regions relevant to mood 
and cognition. ANOVA was used to compare controls with patients and with COPD subgroups 
(oxygen users [n = 9] and nonusers [n = 9]), and only variables showing group differences at 
p  0.05 were included in multiple regressions controlling for age, gender, and education to 
develop the ﬁ  nal model. Controls and COPD patients differed signiﬁ  cantly in global cogni-
tion and memory, mood, and soluble TNFR1 levels but not brain structural or neurochemical 
measures. Multiple regressions identiﬁ  ed pathways linking disease severity with impaired per-
formance on sensitive cognitive processing measures, mediated through oxygen dependence, 
and with systemic inﬂ  ammation (TNFR1), related through poor 6-minute walk performance. 
Oxygen desaturation with activity was related to indicators of brain tissue damage (increased 
frontal choline, which in turn was associated with subcortical white matter attenuation). This 
empirically derived model provides a conceptual framework for future studies of clinical inter-
ventions to protect the brain in patients with COPD, such as earlier oxygen supplementation 
for patients with desaturation during everyday activities.
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Introduction
Impaired brain function has long been recognized as a complication of COPD (see 
Hynninen et al 2005 for a comprehensive review). While cognitive and mood changes 
in COPD have generally been associated with hypoxemia, much of the variance 
remains unexplained, particularly in highly heterogeneous or less well character-
ized subject samples. This exploratory study examines in detail the pathways from 
lung disease to brain dysfunction in a carefully selected group of COPD patients and 
matched controls, using disease-speciﬁ  c measures of disease severity and disability, 
validated measures of mood and cognition, plasma measures of proinﬂ  ammatory 
cytokines, and both structural and neurochemical measures of brain integrity. As 
our intent was to construct a testable working model of COPD and the brain, we 
used a broad conceptual framework and inclusive measurement domains. Initial 
hypotheses were that COPD severity and requirement for oxygen supplementation 
would be related to poorer cognitive processing but not premorbid intelligence; to 
increased proinﬂ  ammatory cytokines, a possible systemic mediator between lung and 
brain; and to signs of structural and neurochemical damage in brain regions known 
to be related to mild cognitive deﬁ  cits and highly sensitive to oxygen deprivation 
(hippocampus and frontal lobes).International Journal of COPD 2008:3(3) 430
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Methods
Subjects were 18 patients with clinically stable COPD 
and 9 age- and gender-matched healthy controls, carefully 
screened to exclude persons with major chronic medical 
comorbidity or use of medications known to be associated 
with cognitive impairment. Clinical laboratory evaluation 
(CBC, extended chemistry panel including albumin) was 
normal for all included subjects and none was clinically 
cachectic (ie, all BMI  20). Pulmonary disease manage-
ment had been optimized by the subject’s usual pulmonary 
physician prior to enrollment; one subject awaiting lung 
transplantation was matched for surgery before completing 
the physiological components of the protocol. No COPD or 
control subject met diagnostic criteria for dementia, current 
major depression, primary panic disorder, or alcohol abuse, 
and none was a current smoker. Table 1 summarizes subject 
characteristics. Patients receiving supplemental oxygen used 
their normal prescribed daytime ﬂ  ow rates during all study 
procedures (cognitive and mood assessment, 6-minute walk, 
and all neuroimaging studies).
Measures of pulmonary function included spirometry, 
pulse oximetry at rest and change during a 6-minute walk, and 
distance walked (Enright 2003). Health status was assessed 
using the St George’s Respiratory Disease Questionnaire 
(SGRQ; Jones et al 2005).
Cognitive measures included the Dementia Rating Scale-2 
(Jurica et al 2001), a measure of global cognitive function-
ing; the Wide Range Achievement Test-3 (Wilkinson 1993), 
a measure of premorbid intelligence; the logical memory 
subtest of the WMS-3 (Wechsler 1997a); and a measure of 
moment-to-moment cognitive processing sensitive to mild 
brain dysfunction, the Digit Symbol coding test (Wechsler 
1997b; Anger et al 2000; Kilburn 2001; Lopez et al 2003).
Depression was assessed using two validated measures, 
the Hamilton Depression Rating Scale (Ham-D, 17 item 
version [Reynolds 1995], a symptom severity scale) and the 
PHQ-9 (Kroenke et al 2001), which yields both symptom 
severity and good reliability with diagnoses of major and 
minor depression. Anxiety was measured with the Patient-
Rated Anxiety Scale (PRAS [Sheehan 1983]) which was 
previously found to be sensitive to both psychological anxi-
ety/worry and somatic symptoms of sympathetic overarousal 
in COPD (Borson et al 1992).
A plasma cytokine panel was assayed on ﬂ  ash-frozen 
plasma collected after completion of questionnaires and 
cognitive tests. IL-1b, IL-2r, IL-6, TNFα, and hsCRP 
were measured using immunoassay kits (Siemens Medical 
Solutions Diagnostics, Los Angeles, CA, USA) on the 
Siemens Immulite (IL-1b, IL-2r, TNFα) and Siemens 
Immulite 2000 (hsCRP and IL-6). Measurement of the 
soluble TNFR1 (also known as TNFR-p55) receptor and 
TNFR2 (TNFR-p75) receptor was performed using enzyme 
immunoassay kits (Biosource International, Camarillo, CA, 
USA) run on the Roche COBAS Core II (Roche Diagnostics, 
Basel, Switzerland). The intra-assay and inter-assay 
coefﬁ  cients of variation are generally 5.0% for all assays 
over the entire assay range, and in no case 10%, according 
to the reagent literature.
Neuroimaging was done on a different day separated by 
up to a week apart from cognitive, mood, 6-minute walk, 
and blood sample acquisition. Measures included structural 
magnetic resonance imaging (MRI) and neurochemical 
imaging with 1H magnetic resonance spectroscopy. A set of 3 
dimensional, high-resolution (1.5 mm) T1-weighted coronal 
MRI images was acquired extending through the entire brain, 
using, a spoiled GRASS (SPGR) sequence (TE 5 ms and 
TR 35 2000 ms; ﬁ  eld of view 24 cm; matrix size 256 × 256; 
ﬂ  ip angle 45°; NEX 1, interleaved with 0 gap). A set of 
axial FLAIR sequences extending through the entire brain 
was also acquired (TR 10,000 ms, TE 130 ms; TI 220; ﬁ  eld 
of view 24 cm; matrix size 256 × 192, NEX1, 3 mm thick, 
interleaved with 0 gap). Global ratings of brain atrophy (T1) 
and subcortical white matter hyperintense lesions (FLAIR) 
were scored by two independent raters and any discrepan-
cies reconciled before analysis. Hippocampal volume was 
measured using previously published quantitative methods 
(Aylward et al 1999).
Table 1 Sample description
Demographics Controls  COPD 
 (n  = 9)  (n = 18)
Age, mean years (SD)  68.2 (5.8)  68.5 (8.0)
Sex (% women)  62%  64%
Education, mean years (SD)  16.8 (2.8)  17.7 (2.5)
Ethnicity (% white)  100%  100%
Pulmonary disease indicators  
GOLD stage (number × stage)   
IIa (FEV1 50%–79% predicted)  na  2
IIb (FEV1 30%–49% predicted)  na  8
III (FEV1  30% predicted)  na  7a
SGRQ mean total (SD)  6 (3)  56 (17)
6 MWD, mean feet (SD)  1545 (196)  922 (262)
Long-term continuous O2 use (n, %)  0  9 (53%)
SpO2, mean resting (SD)  98.1 (1.5)  96.0 (2.2)
SpO2, mean minimum during 6MW (SD)  94.6 (1.7)  88.0 (3.1)
a1 subject dropped out for lung transplant before spirometry measures completed 
Analyses by 1-way ANOVA.
Abbreviations: SGRQ, St. George’s Respiratory Disease Questionnaire total score 
(% possible disability points); 6 MWD, 6-minute walk distance; SpO2, O2 saturation 
by pulse oximeter.International Journal of COPD 2008:3(3) 431
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Neurochemical measures were collected in left frontal 
lobe white matter and left hippocampus using 1H MRS (voxel 
size 15 × 15 × 12 mm and TR/TE 2000/144 ms. MRS data 
were ﬁ  t using custom basis sets in LCModel (Provencher 
1993) and quantiﬁ  ed using a partial volume (tissue) corrected 
unsuppressed water signal. These methods yielded millimolar 
concentrations of N-acetylaspartate + N-acetylaspartyl-
glutamate (NAA+), creatine (Cre, the sum of phophocreatine 
and creatine), and choline-containing compounds (Cho). The 
neurochemical measures have coefﬁ  cients of variation in our 
hands ranging from 3.3% to 5.3% for NAA, Cre, and Cho 
respectively, and reproducibility is equivalent within and 
between sessions (Brooks et al 1999).
Analytic approach and statistical methods
All dependent measures (mood, cognition, cytokines, imag-
ing variables) were ﬁ  rst subjected to one-way ANOVAs 
comparing COPD and control subjects, and COPD oxygen 
users with non-users and controls. After identifying depen-
dent variables associated with COPD group membership 
and/or oxygen use at the p  0.05 level (see Table 2), 
stepwise multiple regression was used to determine which 
of the COPD variables were uniquely associated with 
observed group differences. Major variables describing the 
presence and severity of COPD were used to construct a 
“backbone” comprised of the following: presence or absence 
of COPD; SGRQ total score; FEV1% predicted; oxygen use; 
and 6-minute walk distance and maximum walking-related 
change in oxygen saturation (see Figure 1). The criteria for 
including a variable in the “backbone” were primarily clinical 
(based on the core measures used in COPD assessment and 
staging, eg, SGRQ, FEV1, oxygen dependence), while the 
sequential ordering of the backbone variables was statisti-
cal (see Figure 1). Variables were placed according to their 
strongest “near-neighbor” relationships in regressions. In 
regressions predicting mood, cognition, and brain imaging 
outcomes, in addition to the COPD backbone variables we 
also allowed stepwise entry of age, education and gender to 
control their potential confounding effects. The end result 
of all regressions is summarized in a ﬁ  nal model show-
ing R2 relationships between the relevant variables (see 
Figure 1). In the model, “mood” is a z-score composite of 
three highly intercorrelated scales (Ham-D, PHQ-9, and 
PRAS; all r = 0.7–0.8). To limit Type 1 statistical errors, and 
to increase clarity and robustness in the ﬁ  nal model, only 
relationships with p  0.01 were included. This analytic 
approach simulates structural equation modeling, which is 
precluded here by small sample size.
Results
Descriptive data for the sample are shown in Table 1. Groups 
were well matched across demographic characteristics and 
showed the expected differences in the main lung disease 
related predictor (independent) variables. Group comparisons 
for key outcome (dependent) variables are shown in Table 2. 
Statistically signiﬁ  cant differences between controls and 
the whole COPD group were found for several cognitive 
and mood measures but not for brain structural or neuro-
chemical measures. Both depression measures, the Ham-D 
and PHQ-9, showed group differences. PHQ-9 differed 
between control and combined COPD groups, whereas 
Table 2 Neuropsychiatric, neuroanatomical, and neurochemical 
measures (means and standard deviations)
Domain Controls COPD P control
vs COPD
Cognition n = 9 No O2
(n = 9)
O2 dependent
(n = 9)
WRAT-3 109.1 (9.8) 109.1 (5.9) 103.7 (8.3) ns
DRS-2 Total 12.3 (3.2) 9.0 (3.3) 9.9 (2.2) 0.019
Memory 11.9 (1.7) 10.3 (2.7) 9.6 (2.8) 0.049
WAIS-3
  Digit symbol 12.7 (1.5) 12.1 (1.5) 8.4 (3.3) 0.034a
WMS-3
 Logical  memory 13.7 (2.1) 12.6 (2.1) 10.7 (3.1) 0.049b
Mood (depres-
sion, anxiety)
Ham-D 17 3.4 (2.9) 8.4 (3.3) 12.2 (5.7) 0.001c
PHQ-9 1.3 (1.2) 6.1 (6.2) 6.1 (4.1) 0.005
PRAS 2.8 (3.0) 22.0 (20.7) 29.3 (19.2) 0.002
Brain structure
Hippocampal 
volume
5.4 (0.9) 5.2 (0.8) 4.8 (0.8) ns
White matter 
lesions
2.0 (0.0) 2.7 (0.8) 2.0 (0.9) ns
Neuro-
chemistry
Frontal choline 3.96 (0.38) 3.30 (0.46) 4.50 (0.71) nsd
Hippocampal 
NAA+
12.6 (1.8) 11.9 (2.0) 13.0 (1.7) ns
Inﬂ  ammation
Soluble TNFR1 2.14 (0.50) 2.37 (0.97) 2.71 (0.62) 0.03
All comparisons by 1-way ANOVA with post-hoc tests; p  0.05 reported as ns. For 
cognitive tests, age/education scaled scores reported. For mood scales, total scores 
reported. Hippocampal volume reported as cubic centimeters for right and left hip-
pocampus combined. White matter lesions reported as relative predominance of 
subcortical vs periventricular hyperintensities. Soluble TNF R1 reported as ng/mL.
a O 2 users worse than both other groups (p  0.005).
b O 2 users borderline worse than both other groups (p = 0.05–0.10).
c  All groups signiﬁ  cantly different (p = 0.001).
d O 2 users worse than nonusers and controls (p  0.005).International Journal of COPD 2008:3(3) 432
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Ham-D scores increased linearly across the three groups from 
control (lowest) to hypoxemic/oxygen dependent (highest), 
an increase explained by items rating symptoms of physi-
cal disability rather than depressed mood (data not shown). 
Oxygen-dependent COPD patients fared worse than controls 
and nonoxygen-dependent COPD patients on cognitive as 
well as mood measures.
Brain atrophy, number and estimated volume of white 
matter hyperintensities, and frontal and hippocampal neuro-
chemical indices, did not differ between COPD and control 
groups (not all data shown). Mean hippocampal volume 
was smaller in COPD subjects than controls, with oxygen-
dependent patients having an 11% smaller volume, but these 
differences were not statistically signiﬁ  cant in analyses across 
all subjects. On the other hand, frontal choline was signiﬁ  -
cantly higher in oxygen dependent subjects, consistent with 
evidence of brain damage in this most impaired group.
Circulating proinﬂ  ammatory cytokine levels were highly 
skewed and were therefore rank-transformed before analysis 
(data not shown). Only soluble TNFR1 showed signiﬁ  cant 
group differences, with the highest levels in oxygen-
dependent COPD subjects.
The working model constructed by stepwise regressions 
relating primary COPD variables with multidimensional 
outcome measures (Figure 1) shows the unique variance 
accounted for (R2) at each step.
Discussion
This study replicates known relationships between measures 
of COPD disease severity, general cognition, and mood 
(Grant et al 1987) in a group of subjects with normal premor-
bid intelligence and good educational attainment, selected for 
minimal medical comorbidity. It extends earlier ﬁ  ndings on 
cognition using measures sensitive to mild cognitive impair-
ment (digit symbol substitution). It also provides new insights 
into the mechanisms by which severe ambulatory stages of 
oxygen-dependent COPD may produce cumulative damaging 
effects on the brain. The chain linking oxygen desaturation 
during relatively low-intensity exercise (6-minute walk) to 
elevations in frontal choline, and then to changes in brain 
Figure 1 Modeling the impact of COPD on brain function (R2 shown).
Stepwise multiple regressions with “backbone” variables used as predictors of outcome variables already showing COPD group differences (see text). Numbers next to lines 
connecting domains indicate R2 for the relevant relationship. All effects shown are independent of age, education, and gender.
Variable deﬁ  nitions
Independent variables – COPD backbone:
Group: COPD vs control; Health status: total score, St. Georges Respiratory Questionnaire; FEV1: forced expiratory volume % predicted; Oxygen use: use/nonuse of supple-
mental oxygen; Walk distance: distance (feet) walked in 6 minutes (or to maximum tolerated, if less than 6 minutes); Desaturation with activity: resting SpO2 minus minimum 
SpO2 during walk.
Dependent variables:
Global cognition: total score, Dementia Rating Scale; Mood: z score combination of 17-item Hamilton Depression Scale, Patient Rated Anxiety Scale, and Patient Health Ques-
tionnaire-9; Attention: digit symbol substitution (WAIS); Chronic inﬂ  ammation: soluble tumor necrosis factor receptor 1 (TNFR1); Frontal choline measured in frontal white 
matter by 1H MRS;   White matter changes: subcortical white matter hyperintensities on MRI FLAIR images.
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white matter, appears to be robust (R2 = 0.45–0.48). This 
elevation in brain choline levels cannot be attributed to 
acute oxygen desaturation during the 6-minute walk test, 
as spectroscopy was performed on a different day, and 
oxygen-dependent patients were transported to the scanner 
by wheelchair.
We propose that frequent oxygen desaturation during 
everyday activity may be a key mechanism underlying the 
damage to brain tissue reﬂ  ected in elevated brain choline. 
Similar choline elevations are observed in systemic diseases 
secondarily associated with brain tissue breakdown and 
cognitive impairment (Friedman et al 1998, 1999; Forton 
et al 2005), and appear to reﬂ  ect damage to myelin and 
increased turnover of neuronal membrane precursors (Ross 
and Michaelis 1994). It is likely that increases in choline 
in advanced hypoxemic COPD reﬂ  ect such a combination 
of membrane breakdown and turnover changes in the brain, 
and that these are eventually manifested as white matter 
hyperintensities on structural imaging. Other spectroscopy 
approaches (eg, decoupled 31P MRS) to measure individual 
constituents of the choline peak could be helpful in reﬁ  ning 
and further interpreting these results.
Elevation of frontal choline in oxygen-dependent COPD 
patients is consistent with the work of Incalzi et al (2003) 
using a different (perfusion) imaging approach. In that 
comprehensive mapping study, substantial perfusion deﬁ  cits 
were identiﬁ  ed in frontal lobes and were most marked in 
oxygen-dependent subjects. Only one previous study used 
1H MRS to measure brain neurochemical species in patients 
with COPD (Shim et al 2001). Shim et al reported decreases 
in NAA, creatine, and choline in COPD subjects relative 
to controls, whereas we found no differences in NAA or 
creatine and an elevation in choline, and this was limited to 
oxygen-dependent subjects. However, in the Shim study, 
oxygen dependent subjects were excluded, participants were 
younger, analyses were not adjusted for age and education, 
and the brain regions sampled were different from those used 
in the present study and possibly less likely to be related to 
changes in mood and cognition.
In the present study, we also found evidence of chronic 
systemic inﬂ  ammation, measured as an elevation of TNFR1, 
in chronically hypoxemic patients, an effect associated with 
exercise limitation (impaired 6-minute walk distance). We 
did not examine acute cytokine responses to exercise in 
this study; a previous study in 11 GOLD Stage IIb patients 
found an abnormally elevated systemic TNFα response to a 
single session of moderate acute exercise, but no acute effect 
of exercise on TNFR1 (Rabinovich et al 2003). TNFR1, 
in contrast to TNFα, most likely reﬂ  ects the presence of 
a chronic, but not acute, systemic inﬂ  ammatory milieu. 
Such a milieu might be promoted by repeated inﬂ  ammatory 
responses to everyday exertion in oxygen-dependent patients. 
This theory is consistent with data showing elevated TNFR1 
levels in both typical inﬂ  ammatory diseases (rheumatoid 
arthritis [Gattorno et al 1996; Maury et al 2003]) and dis-
eases in which the role of chronic systemic inﬂ  ammation has 
only recently emerged (eg, ischemic cardiovascular disease 
[Cesari et al 2003]). These studies suggest that TNFR1 
may be among the most sensitive indicators of long-term 
systemic inﬂ  ammation in many different chronic diseases, 
now including COPD.
Implications
This study was designed to develop a testable multidi-
mensional model of the emergence of brain dysfunction in 
patients living with COPD. Although many studies have 
found relationships between depression, anxiety, and cog-
nition in COPD patients that are generally more apparent 
with greater disease severity, the present study explicitly 
traces a pathway leading from symptoms through objective 
measures of pulmonary disease to brain dysfunction that 
may occur with disease progression. We conﬁ  rmed that 
the presence of COPD is associated with mild decrements 
in mood and cognition. Severe disease is associated with 
evidence of chronic systemic inflammation (elevated 
TNFR1) and subtle cognitive deﬁ  cits (digit symbol). Levels 
of oxygen desaturation that are likely to occur with every-
day activities in severe COPD appear to mediate speciﬁ  c 
changes in brain neurochemistry and structure that suggest 
sustained brain damage. The strong relationships we report 
in the working model presented here are likely to survive 
replication in larger samples, as the effect sizes we found 
for 14 of 15 R2 relationships qualify as large (Cohen and 
Cohen 1983).
The cross sectional model presented here would require 
testing in prospective research designs to evaluate its abil-
ity to predict longitudinal decline in cognition and incident 
damage to brain tissue integrity. However, such damage, once 
it has occurred, may not be reversible. While the evidence is 
limited, it appears that the cognitive impairment reported 
in advanced COPD is only partially reversible with oxygen 
therapy started late in the disease course (Heaton et al 1983). 
If our model is correct, routine identiﬁ  cation of episodic 
desaturation with everyday activity, and/or sleep, and earlier 
oxygen supplementation, could help to prevent irreversible 
brain damage in COPD patients.International Journal of COPD 2008:3(3) 434
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